| Nov 21 |
Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
|
| Nov 21 |
Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
|
| Nov 21 |
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
|
| Nov 19 |
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
|
| Nov 19 |
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
|
| Nov 19 |
Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment
|
| Nov 18 |
Jazz Pharmaceuticals: High Uncertainty, Low Risk
|
| Nov 18 |
Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now?
|
| Nov 14 |
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
|
| Nov 14 |
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest
|
